These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 19150421

  • 21. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 22. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
    Allen MR, Turek JJ, Phipps RJ, Burr DB.
    Bone; 2011 Jul; 49(1):128-32. PubMed ID: 20637914
    [Abstract] [Full Text] [Related]

  • 23. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA.
    J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
    [Abstract] [Full Text] [Related]

  • 24. Effects of intravenous EDTA treatment on serum parathyroid hormone (1-84) and biochemical markers of bone turnover.
    Guldager B, Brixen KT, Jørgensen SJ, Nielsen HK, Mosekilde L, Jelnes R.
    Dan Med Bull; 1993 Nov; 40(5):627-30. PubMed ID: 8299406
    [Abstract] [Full Text] [Related]

  • 25. Biomarkers of bone health and osteoporosis risk.
    Eastell R, Hannon RA.
    Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989
    [Abstract] [Full Text] [Related]

  • 26. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
    Sebastián-Ochoa A, Fernández-García D, Reyes-García R, Mezquita-Raya P, Rozas-Moreno P, Alonso-Garcia G, Muñoz-Torres M.
    Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
    [Abstract] [Full Text] [Related]

  • 27. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S, Fukawa T, Kamiya S.
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [Abstract] [Full Text] [Related]

  • 28. Comparing the effect of short term post meals and bedtime calcium supplementation on the C-terminal telopeptide crosslinks and PTH levels in postmenopausal osteopenic women.
    Chuengsamarn S, Suwanwalaikorn S.
    J Med Assoc Thai; 2005 Jun; 88 Suppl 1():S12-20. PubMed ID: 16858933
    [Abstract] [Full Text] [Related]

  • 29. [Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers].
    Hasegawa M, Ichimura S, Satomi K.
    Clin Calcium; 2010 Mar; 20(3):413-20. PubMed ID: 20190372
    [Abstract] [Full Text] [Related]

  • 30. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

  • 31. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC.
    Curr Med Res Opin; 2003 Jun 20; 19(5):383-94. PubMed ID: 13678475
    [Abstract] [Full Text] [Related]

  • 32. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr 20; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R, Blackhouse G, Adachi J.
    Curr Med Res Opin; 2006 Jul 20; 22(7):1425-36. PubMed ID: 16834841
    [Abstract] [Full Text] [Related]

  • 34. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Ballaouri I, Efstathiadou Z, Kita M, Avramidis A.
    Clin Endocrinol (Oxf); 2009 Apr 20; 70(4):522-6. PubMed ID: 18625000
    [Abstract] [Full Text] [Related]

  • 35. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP.
    Bone; 2011 Dec 20; 49(6):1160-5. PubMed ID: 21893225
    [Abstract] [Full Text] [Related]

  • 36. Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling.
    Pineda B, Hermenegildo C, Tarín JJ, Cano A, García-Pérez MÁ.
    Menopause; 2012 Mar 20; 19(3):319-27. PubMed ID: 22067277
    [Abstract] [Full Text] [Related]

  • 37. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K.
    J Bone Miner Res; 2010 Jan 20; 25(1):48-55. PubMed ID: 19580465
    [Abstract] [Full Text] [Related]

  • 38. Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
    Asaba Y, Hiramatsu K, Matsui Y, Harada A, Nimura Y, Katagiri N, Kobayashi T, Takewaka T, Ito M, Niida S, Ikeda K.
    Bone; 2006 Dec 20; 39(6):1276-82. PubMed ID: 16942925
    [Abstract] [Full Text] [Related]

  • 39. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P, Stancíková M, Letkovská A, Rovenský J.
    Vnitr Lek; 2002 Oct 20; 48(10):943-7. PubMed ID: 16737141
    [Abstract] [Full Text] [Related]

  • 40. Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate.
    Palacios S, Neyro JL, Ferrer J, Villero J, Cañada E, Redondo E, Caloto MT, Nocea G, NTx Study Group.
    Menopause; 2012 Jan 20; 19(1):67-74. PubMed ID: 21926927
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.